Based on these findings, c-MYC and HIF-1α have been identified as potential therapeutic targets in colon cancer [354], which could theoretically lead to clinical trials targeting these factors to promote anti-tumor activity. This evidence concerns the gene MYC and malignant colon neoplasm.